{
  "id": "602357ff1cb411341a00009a",
  "type": "factoid",
  "question": "What treatment was studied in the KEYNOTE-522 trial?",
  "ideal_answer": "KEYNOTE-522 trial studied adjuvant pembrolizumab for patients with triple-negative breast cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32396855",
    "http://www.ncbi.nlm.nih.gov/pubmed/34468351",
    "http://www.ncbi.nlm.nih.gov/pubmed/32709714",
    "http://www.ncbi.nlm.nih.gov/pubmed/32101663",
    "http://www.ncbi.nlm.nih.gov/pubmed/31420357",
    "http://www.ncbi.nlm.nih.gov/pubmed/32870473"
  ],
  "snippets": [
    {
      "text": "The phase 3 KEYNOTE-522 trial now shows that the addition of pembrolizumab to chemotherapy improves pathological complete response rates regardless of PD-L1 status and appears to improve survival.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32396855",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear.METHODS: In this phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin (784 patients; the pembrolizumab-chemotherapy group) or placebo every 3 weeks plus paclitaxel and carboplatin (390 patients; the placebo-chemotherapy group); the two groups then received an additional four cycles of pembrolizumab or placebo, and both groups received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32101663",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32101663",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: In both the IMpassion 130 trial in the metastatic setting and in Keynote 522 in the neoadjuvant setting, patients with triple-negative breast cancer (TNBC) showed benefit from PD-1 axis immunotherapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32709714",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Additionally, in light of the results of the KEYNOTE-522 study of adjuvant pembrolizumab in TNBC, evaluation of immunotherapy in the early disease setting is a subject of great interest. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32870473",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pembrolizumab plus chemotherapy may be an effective neoadjuvant treatment for triple-negative breast cancer. In the phase III KEYNOTE-522 trial, patients treated with the PD-1 inhibitor in combination with chemotherapy prior to surgery were more likely to have a pathologic complete response than patients who received chemotherapy alone, regardless of PD-L1 levels.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31420357",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Additionally, in light of the results of the KEYNOTE-522 study of adjuvant pembrolizumab in TNBC, evaluation of immunotherapy in the early disease setting is a subject of great interest.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32870473",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " in light of the results of the KEYNOTE-522 study of adjuvant pembrolizumab in TNBC, evaluation of immunotherapy in the early disease setting is a subject of great interest. This review a",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32870473",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pembrolizumab plus chemotherapy may be an effective neoadjuvant therapy in patients with early-stage triple-negative breast cancer: In an interim analysis of the phase III KEYNOTE-522 trial, patients treated with the combination had a higher pathologic complete response rate and trended toward better event-free survival than those who received chemotherapy alone.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34468351",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "pembrolizumab"
}